Clinical Trials · NCT00983021
Safety and Tolerability of NN9068 in Healthy Male Volunteers
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 24
- Start date
- Sep 2009
- Locations
- 1 site, Germany
- Primary endpoint
- Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes